Search Results

MITHRAS Evaluates Interventional Closure of Residual Atrial Septal Defect After TMVR

October 15, 2020—The MITHRAS randomized clinical trial found that interventional closure of an iatrogenic atrial septal defect (iASD) driven by transcatheter mitral valve repair (TMVR) was not superior to conservative medical treatment with regard to the primary endpoint of change in 6-minute walking distance.

Edwards Evoque Transcatheter Tricuspid Valve Replacement System Receives CE Mark Approval

October 19, 2023—Edwards Lifesciences Corporation announced that the company’s Evoque tricuspid valve replacement system has received CE Mark approval for the transcatheter treatment of eligible patients with tricuspid regurgitation (TR) in Europe.

Abbott Presents Late-Breaking Data From Transcatheter Valve and Structural Heart Portfolios

May 19, 2022—Abbott announced two late-breaking data presentations evaluating the company’s TriClip minimally invasive tricuspid heart valve repair device and the Navitor, its latest-generation transcatheter aortic valve replacement/implantation (TAVR/TAVI) system.

Abbott’s TriClip TEER Device Evaluated in Real-World bRIGHT Study

May 17, 2023—Abbott announced 30-day outcomes from the bRIGHT study of the company’s TriClip transcatheter edge-to-edge repair (TEER) system for treating real-world patients with tricuspid regurgitation (TR).

Abbott’s TriClip G4 for Tricuspid Regurgitation Receives CE Mark

April 8, 2021—Abbott announced it has received CE Mark approval for its next-generation TriClip transcatheter tricuspid valve repair system.